Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given an average recommendation of “Hold” by the nine research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $3.00.

A number of analysts have recently issued reports on the company. Wedbush reaffirmed an “ourperform” rating and issued a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday. Chardan Capital lowered their price target on Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating on the stock in a research note on Tuesday, June 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. BMO Capital Markets reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Monday, May 15th. Finally, ValuEngine lowered Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/regulus-therapeutics-inc-nasdaqrgls-given-consensus-recommendation-of-hold-by-brokerages.html.

In other news, Director William H. Rastetter purchased 274,725 shares of the stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, with a total value of $249,999.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel R. Chevallard purchased 54,945 shares of the stock in a transaction dated Tuesday, July 25th. The stock was purchased at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the purchase, the chief financial officer now directly owns 59,415 shares of the company’s stock, valued at $54,067.65. The disclosure for this purchase can be found here. Insiders bought 549,450 shares of company stock worth $500,000 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Teachers Advisors LLC raised its stake in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares in the last quarter. Wedbush Securities Inc. raised its position in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 18,600 shares during the period. Tudor Investment Corp ET AL raised its position in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the period. Wells Fargo & Company MN raised its position in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the period. Finally, LMR Partners LLP bought a new position in Regulus Therapeutics during the second quarter worth $164,000. 21.09% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics (NASDAQ:RGLS) traded down 1.9630% on Tuesday, hitting $0.9689. The stock had a trading volume of 50,527 shares. Regulus Therapeutics has a 12 month low of $0.86 and a 12 month high of $3.82. The company’s market cap is $51.53 million. The company has a 50-day moving average of $1.00 and a 200 day moving average of $1.35.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.10. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. On average, analysts predict that Regulus Therapeutics will post ($1.10) EPS for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.